JP2013209421A5 - - Google Patents

Download PDF

Info

Publication number
JP2013209421A5
JP2013209421A5 JP2013124713A JP2013124713A JP2013209421A5 JP 2013209421 A5 JP2013209421 A5 JP 2013209421A5 JP 2013124713 A JP2013124713 A JP 2013124713A JP 2013124713 A JP2013124713 A JP 2013124713A JP 2013209421 A5 JP2013209421 A5 JP 2013209421A5
Authority
JP
Japan
Prior art keywords
composition
live attenuated
virus
kit
attenuated virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013124713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013209421A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013209421A publication Critical patent/JP2013209421A/ja
Publication of JP2013209421A5 publication Critical patent/JP2013209421A5/ja
Withdrawn legal-status Critical Current

Links

JP2013124713A 2007-04-06 2013-06-13 弱毒生ウイルス組成物 Withdrawn JP2013209421A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91057907P 2007-04-06 2007-04-06
US60/910,579 2007-04-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010502331A Division JP5296775B2 (ja) 2007-04-06 2008-04-04 弱毒生ウイルスのための方法および組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015245040A Division JP2016041753A (ja) 2007-04-06 2015-12-16 弱毒生ウイルス組成物

Publications (2)

Publication Number Publication Date
JP2013209421A JP2013209421A (ja) 2013-10-10
JP2013209421A5 true JP2013209421A5 (https=) 2014-03-13

Family

ID=39827288

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010502331A Active JP5296775B2 (ja) 2007-04-06 2008-04-04 弱毒生ウイルスのための方法および組成物
JP2013124713A Withdrawn JP2013209421A (ja) 2007-04-06 2013-06-13 弱毒生ウイルス組成物
JP2015245040A Withdrawn JP2016041753A (ja) 2007-04-06 2015-12-16 弱毒生ウイルス組成物
JP2019105370A Active JP6817370B2 (ja) 2007-04-06 2019-06-05 弱毒生ウイルス組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010502331A Active JP5296775B2 (ja) 2007-04-06 2008-04-04 弱毒生ウイルスのための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015245040A Withdrawn JP2016041753A (ja) 2007-04-06 2015-12-16 弱毒生ウイルス組成物
JP2019105370A Active JP6817370B2 (ja) 2007-04-06 2019-06-05 弱毒生ウイルス組成物

Country Status (28)

Country Link
US (4) US8084039B2 (https=)
EP (2) EP2144998B1 (https=)
JP (4) JP5296775B2 (https=)
KR (4) KR102134980B1 (https=)
CN (4) CN104998257A (https=)
AU (1) AU2008279576C1 (https=)
BR (1) BRPI0809663B8 (https=)
CA (1) CA2720570C (https=)
CO (1) CO6260150A2 (https=)
CU (1) CU20090169A7 (https=)
CY (1) CY1118958T1 (https=)
DK (1) DK2144998T3 (https=)
ES (1) ES2621511T3 (https=)
HK (1) HK1217168A1 (https=)
HR (1) HRP20170513T1 (https=)
HU (1) HUE031617T2 (https=)
IL (3) IL201429A (https=)
LT (1) LT2144998T (https=)
MX (2) MX2009010798A (https=)
MY (3) MY180465A (https=)
NZ (2) NZ580978A (https=)
PH (1) PH12015500773B1 (https=)
PL (1) PL2144998T3 (https=)
PT (1) PT2144998T (https=)
SG (2) SG10201508397VA (https=)
SI (1) SI2144998T1 (https=)
WO (1) WO2009014774A1 (https=)
ZA (2) ZA200907790B (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009014774A1 (en) * 2007-04-06 2009-01-29 Inviragen, Inc. Methods and compositions for live attenuated viruses
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
US7998488B2 (en) * 2008-11-14 2011-08-16 Baxter International Inc. Vaccine formulations and uses thereof
AU2009322175B2 (en) * 2008-12-05 2014-10-09 Takeda Vaccines, Inc. Compositions, methods and uses for inducing viral growth
ES2530049T3 (es) 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composición que comprende gotas de aceite
CN102573802A (zh) 2009-08-12 2012-07-11 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
EP2646051A4 (en) 2010-12-02 2014-05-28 Oncolytics Biotech Inc FORMULATIONS OF LIQUID VIRUSES
MX349294B (es) 2010-12-02 2017-07-21 Oncolytics Biotech Inc Formulaciones virales liofilizadas.
US20120219590A1 (en) * 2011-02-24 2012-08-30 Paxvax, Inc. Formulations useful for spray drying vaccines
EP2714076A1 (en) * 2011-05-26 2014-04-09 GlaxoSmithKline Biologicals S.A. Inactivated dengue virus vaccine
WO2013001034A1 (en) * 2011-06-28 2013-01-03 Leukocare Ag Novel stabilisation method for viruses or bacteria
EP3246400B1 (en) 2012-01-09 2019-10-23 Sanofi Pasteur Biologics, LLC Purification of herpes virus
EP2852662B1 (en) 2012-05-21 2020-09-16 Sanofi Pasteur Limited Herpesvirus compositions and related methods
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US9314519B2 (en) * 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
AP2015008733A0 (en) 2013-03-14 2015-09-30 Takeda Vaccines Inc Compositions and methods for live, attenuated alphavirus formulations
US9480739B2 (en) * 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
CN105636609A (zh) * 2013-10-25 2016-06-01 白血球保健股份有限公司 一种新颖的生产稳定疫苗的方法
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
CN103877565A (zh) * 2014-02-24 2014-06-25 黄淮学院 治疗膀胱癌的基因针剂及其制备方法
JP6716582B2 (ja) 2014-11-07 2020-07-01 サブリミティ・セラピューティクス・リミテッドSublimity Therapeutics Limited シクロスポリンを含む組成物
ES2948037T3 (es) * 2014-12-18 2023-08-30 Amgen Inc Formulación estable congelada del virus del herpes simple
WO2016154055A1 (en) * 2015-03-20 2016-09-29 Bluebird Bio, Inc. Vector formulations
CN104984357B (zh) * 2015-06-02 2018-01-30 长春百克生物科技股份公司 不含明胶的疫苗保护剂组合物及流感减毒活疫苗
TWI569806B (zh) * 2015-06-10 2017-02-11 輔英科技大學 Stabilizer compositions for vaccines and methods for their preparation and swine fever vaccine containing the same
WO2017056101A1 (en) 2015-09-30 2017-04-06 Panacea Biotec Limited Stable live attenuated recombinant dengue vaccine
BE1024160B9 (fr) * 2015-12-22 2017-12-06 Glaxosmithkline Biologicals Sa Formulation immunogène
AR107262A1 (es) * 2016-01-27 2018-04-11 Lilly Co Eli Inactivación de patógenos por delipidación
WO2017142069A1 (ja) * 2016-02-18 2017-08-24 学校法人慶應義塾 細胞培養培地、培養方法、及びオルガノイド
CN109069559A (zh) 2016-04-14 2018-12-21 崔泽尔有限公司 病毒载体稳定化
CN105925541A (zh) * 2016-05-13 2016-09-07 云南省畜牧兽医科学院 一种蓝舌病病毒冻存保护剂及冻存方法
TW202309276A (zh) * 2016-08-03 2023-03-01 美商武田疫苗股份有限公司 用於與經改良之調配物一起穩定黃病毒的組成物及方法
CA3062549A1 (en) * 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
CN107475204A (zh) * 2017-08-03 2017-12-15 中国人民解放军军事医学科学院军事兽医研究所 一种囊膜病毒保护剂及其制备方法
CN107233576B (zh) * 2017-08-08 2020-02-07 江苏省农业科学院 耐热保护剂、猪瘟可室温保存活疫苗及其制备方法和应用
US20210299247A1 (en) * 2017-11-01 2021-09-30 Merck Sharp & Dohme Corp. Stable formulations of cytomegalovirus
WO2019112921A1 (en) 2017-12-07 2019-06-13 Merck Sharp & Dohme Corp. Formulations of dengue virus vaccine compositions
AU2019336940B2 (en) * 2018-09-06 2025-09-11 Bavarian Nordic A/S Storage improved poxvirus compositions
US20220193222A1 (en) * 2018-11-30 2022-06-23 Vaccine Stabilization Institute Viral formulations containing amino acids
MX2021007639A (es) 2018-12-27 2021-08-11 Amgen Inc Formulaciones de virus liofilizadas.
US20210322542A1 (en) * 2020-04-11 2021-10-21 Qiyi Xie Vaccination against coronavirus with poliomyelitis vaccine
ES2988154T3 (es) * 2020-04-11 2024-11-19 Qiyi Xie Vacunación contra coronavirus con vacuna de poliomielitis
WO2022037248A1 (en) * 2020-08-19 2022-02-24 Versitech Limited Live attenuated sars-cov-2 virus immunogenic compositions, methods of making and using
WO2024073860A1 (en) * 2022-10-07 2024-04-11 Elarex Inc. Stabilization of virus-based therapeutic agent
TW202535439A (zh) * 2023-11-17 2025-09-16 美商賽諾菲巴斯德公司 海藻糖疫苗調配物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (fr) 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
FR2742756B1 (fr) * 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US6616931B1 (en) 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
WO1999006068A2 (en) * 1997-07-31 1999-02-11 Hawaii Biotechnology Group, Inc. Recombinant dimeric envelope vaccine against flaviviral infection
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
US6163606A (en) * 1998-09-16 2000-12-19 Lucent Technologies Inc. System for providing virtual called party identification in a voice mail system
CN1053590C (zh) 1998-10-19 2000-06-21 卫生部长春生物制品研究所 冻干甲型肝炎减毒活疫苗及其保护剂
CN1062770C (zh) * 1998-11-12 2001-03-07 卫生部长春生物制品研究所 甲肝-麻疹二联疫苗及其生产方法
ES2290028T3 (es) 1999-05-04 2008-02-16 Anhydro Limited Metodo para la conservacion de virus y micoplasma.
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
ATE526411T1 (de) * 2000-02-16 2011-10-15 Us Gov Health & Human Serv Avirulente, immunogene flavivirus-chimäre
AT410634B (de) * 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
CA2469623C (en) * 2001-12-12 2012-05-29 F H Faulding & Co Limited Composition for the preservation of viruses
US7476390B2 (en) * 2002-02-26 2009-01-13 Maxygen, Inc. Flavivirus antigens
US8293530B2 (en) 2006-10-17 2012-10-23 Carnegie Mellon University Method and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
WO2003087327A2 (en) * 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
US20040042972A1 (en) 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
WO2003086433A1 (en) 2002-04-15 2003-10-23 Tetsuo Santo Therapeutic cream for dermatitis
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
US6873807B2 (en) * 2003-03-20 2005-03-29 Kabushiki Kaisha Toshiba Image forming apparatus
US7588774B2 (en) * 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
US7294455B2 (en) * 2003-05-16 2007-11-13 The University Of North Carolina At Chapel Hill Fixed-dried platelets cross-linked to protein
JP2007516968A (ja) * 2003-12-05 2007-06-28 ベクトン・ディキンソン・アンド・カンパニー 皮内コンパートメントにおける免疫応答を増強する方法、およびそれらの方法で有用な化合物
US20050202046A1 (en) 2004-03-11 2005-09-15 Wyeth Canine vaccine for protection against ehrlichiosis
WO2005120540A2 (en) 2004-06-09 2005-12-22 Schering Aktiengesellschaft Interferon alpha or beta for treatment of cardiomyopathy and endothelial dysfunction
EP1645283A1 (en) * 2004-10-08 2006-04-12 Chiron Behring GmbH & Co. KG Combination vaccine
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
WO2009014774A1 (en) * 2007-04-06 2009-01-29 Inviragen, Inc. Methods and compositions for live attenuated viruses

Similar Documents

Publication Publication Date Title
JP2013209421A5 (https=)
JP2019172686A5 (https=)
HRP20170513T1 (hr) Postupci i pripravci za žive oslabljene viruse
Patil et al. Evaluation of platelet augmentation activity of Carica papaya leaf aqueous extract in rats
Smith et al. Animal models of viral hemorrhagic fever
MY194294A (en) Novel viral replication inhibitors
JP2009504654A5 (https=)
WO2017156511A8 (en) Live attenuated zika virus vaccine
HRP20201696T1 (hr) Farmaceutska parenteralna formulacija koja sadrži kargluminsku kiselinu
JP2016513658A5 (https=)
Giardino et al. SARS-CoV-2 infection in the immunodeficient host: necessary and dispensable immune pathways
Abbas Hepatitis D in pakistan
CN107106489A (zh) 用于丙型肝炎的长效药物组合物
JP2008505901A5 (https=)
JP2018523648A5 (https=)
Vargas-Soler et al. Measles in pediatrics: the resurgence of a vaccine-preventable disease
Sahin et al. A child with an unusual complication of Crimean-Congo hemorrhagic fever: Hemorrhagic pleural effusion
Martinello et al. Direct-acting antivirals for acute HCV: how short can we go?
Rabbad et al. Prevalence of hepatitis G virus infection among chronic hepatitis B, chronic hepatitis C and HIV patients in Sana'a, Yemen
Ghannad et al. Prevalence of hepatitis B and hepatitis C in patients referred to health centers in the Hamadan province, Iran: an epidemiologic study of infections between 2004 and 2007
Al-Greti Prevalence of hepatitis C virus in beta-thalassemia major patients at Karbala governorate
RU2008130944A (ru) Гипериммунная поливалентная сыворотка против массовых вирусных болезней крупного рогатого скота (спви-крс) и способ ее применения
Kishor et al. A review ON etio-pathogenesis OF dengue fever and its management-an updated review
Pithon Severe hemorrhage in a patient with dengue hemorrhagic fever after insertion of orthodontic mini-implants. A case report
Amirova et al. BIOLOGICALLY SUBSTANTIATED, SAFE, AND CORRECTIVE REMEDIES FOR SARS-COV-2 REGIMEN